Study design
Sepsis
SEPSIS
This study was a single-center, prospective, and randomized controlled study. Patients were randomly divided into the Esmolol group (Group E) and the conventional treatment group (Group C) using the random number table method, each with 50 cases. Both groups were treated under the guidance of Surviving Sepsis Campaign – 2018, and achieved the goal of having a CVP greater than 10 mmHg and a negative volume reactivity within 24 h. Only norepinephrine was used to maintain blood pressure throughout the treatment, and other inotropes and vasopressors were not added.